

Bone-targeting of quinolones conjugated with an acidic oligopeptide

著者	Takahashi Tatsuo, Yokogawa Koichi, Sakura Naoki, Nomura Masaaki, Kobayashi Shinjiro, Miyamoto Kenichi
journal or publication title	Pharmaceutical Research
volume	25
number	12
page range	2881-2888
year	2008-12-01
URL	http://hdl.handle.net/2297/14387

doi: 10.1007/s11095-008-9605-4

Editorial Manager(tm) for Pharmaceutical Research
Manuscript Draft

Manuscript Number: PharmRes3191R1

Title: Bone-targeting of quinolones conjugated with an acidic oligopeptide

Article Type: Th Iss: Musculoskeletal Diseases; Wang

Section/Category: Drug delivery and targeting

Keywords: drug delivery system; acidic oligopeptide; osteomyelitis; levofloxacin; norfloxacin

Corresponding Author: Dr. Ken-ichi Miyamoto, PhD

Corresponding Author's Institution: Kanazawa University

First Author: Tatsuo Takahashi, Ph.D.

Order of Authors: Tatsuo Takahashi, Ph.D.; Koichi Yokogawa, Ph.D.; Naoki Sakura, Ph.D.; Masaaki Nomura, Ph.D.; Shinjiro Kobayashi, Ph.D.; Ken-ichi Miyamoto, Ph.D.

Manuscript Region of Origin:

Abstract: Purpose: Osteomyelitis is a progressive infectious process resulting in inflammatory destruction and necrosis of bone. The long-term administration of high-dosage antibiotics is required to treat osteomyelitis, owing to the limited distribution of antibiotics within bone. Therefore, targeted delivery of antibiotics to bone promises to improve therapeutic effectiveness. Methods: We synthesized quinolones such as levofloxacin and norfloxacin conjugated to an acidic oligopeptide, which works as a bone-targeting carrier after systemic administration. The therapeutic effectiveness of the conjugated quinolones in osteomyelitis was evaluated using a mouse model of osteomyelitis, created by inoculating *Staphylococcus aureus* into the tibia of mice. Results: With intravenous injection, the conjugated quinolones selectively distributed to bone, reaching concentrations up to 100-fold those of non-conjugated quinolones. Single intravenous injection of levofloxacin as well as conjugated levofloxacin exhibited antibiotic effects in the osteomyelitis mouse model; conversely, neither conjugated nor non-conjugated norfloxacin was effective. The antibiotic effect of conjugated levofloxacin persisted to at least 6 days after injection, whereas the effect

of non-conjugated levofloxacin was temporary. Conclusion: The selective bone delivery of quinolones conjugated with an acidic oligopeptide may be effective in treating osteomyelitis, although the resulting concentration of antibiotic may be insufficient to completely kill *S. aureus*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Research paper

Bone-targeting of quinolones conjugated with an acidic oligopeptide

Tatsuo Takahashi^a, Koichi Yokogawa^b, Naoki Sakura^c, Masaaki Nomura^a, Shinjiro Kobayashi^{a, d},
Ken-ichi Miyamoto^{b, *}

^aDepartment of Clinical Pharmacology and ^cDepartment of Biosynthetic Chemistry; Faculty of
Pharmaceutical Sciences

^dOrganization for Frontier Research in Preventive Pharmaceutical Sciences, Hokuriku University,
Kanazawa 920-1181, Japan

^bDepartment of Medicinal Informatics; Graduate School of Medical Science, Kanazawa
University, Kanazawa 920-8641, Japan

* To whom correspondence should be addressed: Department of Medicinal Informatics,
Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa
920-8641, Japan

Tel: +81-76-265-2045; Fax: +81-76-234-4280; E-mail: miyaken@pharmacy.m.kanazawa-u.ac.jp

1
2
3
4
5
6 **Abstract**

7 **Purpose:** Osteomyelitis is a progressive infectious process resulting in inflammatory
8 destruction and necrosis of bone. The long-term administration of high-dosage antibiotics is
9 required to treat osteomyelitis, owing to the limited distribution of antibiotics within bone.
10 Therefore, targeted delivery of antibiotics to bone promises to improve therapeutic effectiveness.

11 **Methods:** We synthesized quinolones such as levofloxacin and norfloxacin conjugated to an
12 acidic oligopeptide, which works as a bone-targeting carrier after systemic administration. The
13 therapeutic effectiveness of the conjugated quinolones in osteomyelitis was evaluated using a
14 mouse model of osteomyelitis, created by inoculating *Staphylococcus aureus* into the tibia of
15 mice. **Results:** With intravenous injection, the conjugated quinolones selectively distributed to
16 bone, reaching concentrations up to 100-fold those of non-conjugated quinolones. Single
17 intravenous injection of levofloxacin as well as conjugated levofloxacin exhibited antibiotic
18 effects in the osteomyelitis mouse model; conversely, neither conjugated nor non-conjugated
19 norfloxacin was effective. The antibiotic effect of conjugated levofloxacin persisted to at least 6
20 days after injection, whereas the effect of non-conjugated levofloxacin was temporary.

21 **Conclusion:** The selective bone delivery of quinolones conjugated with an acidic oligopeptide
22 may be effective in treating osteomyelitis, although the resulting concentration of antibiotic may
23 be insufficient to completely kill *S. aureus*.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Key words:** drug delivery system, acidic oligopeptide, osteomyelitis, levofloxacin, norfloxacin
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 **Introduction**

7 Osteomyelitis is an inflammation of bone marrow and surrounding cortical bone that
8 results in bone destruction and necrosis. Historically, osteomyelitis has been categorized as acute,
9 subacute, or chronic based on the time of disease onset. Acute osteomyelitis develops within 2
10 weeks after disease onset; subacute osteomyelitis, within one to several months; and chronic
11 osteomyelitis, after a few months. *Staphylococcus aureus* is commonly implicated in most cases
12 of acute and chronic osteomyelitis and is responsible for up to 90% of acute hematogenous
13 osteomyelitis in children. In adults, osteomyelitis most often results from the contiguous spread
14 of microbes, usually involving multiple organisms (1-4). Acute hematogenous osteomyelitis is
15 managed by careful evaluation of microbial etiology and susceptibility, and a 4- to 6-week course
16 of appropriate antibiotic therapy (5). Chronic osteomyelitis is generally treated with surgical
17 debridement and the administration of parental antibiotics such as β -lactams or aminoglycosides.
18 Without adequate debridement, most antibiotic regimens fail, even with prolonged therapy. After
19 the removal of necrotic tissue, the remaining bed of tissues must be considered to be
20 contaminated with the responsible pathogens. Antibiotic treatment for at least 4 weeks is
21 recommended (3, 6, 7). Moreover, the serum bactericidal titer, which is defined as the maximal
22 dilution of serum able to kill the infecting organism *in vitro*, should be at least 1:2 for acute
23 osteomyelitis treatment and at least 1:4 for chronic osteomyelitis treatment (8). The long-term
24 administration of high-dosage antibiotics is required to treat osteomyelitis, owing to a lack of
25 antibiotic penetration into bone tissue.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Various studies have suggested that the local application of antibiotics using
45 antibiotic-impregnated bioimplants such as polymethylmethacrylate beads, hydroxyapatite bone
46 cement, or biodegradable microspheres provide higher local antibiotic concentrations than those
47 achievable with intravenous administration, with the additional advantage of avoiding toxicity
48 associated with high levels of drug in the plasma (9-14). However, the bioimplant methodology
49 appears to be useful only in chronic osteomyelitis, because surgical debridement is not necessary
50 in acute osteomyelitis. Furthermore, the invasive procedure required for placing bioimplants may
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 result in secondary bone infections. Therefore, the development of non-invasive approaches,
6 including oral antibiotics that target the bone, can enhance the clinical accessibility and
7 convenience of antibiotic therapy for osteomyelitis patients.
8
9

10
11 Recently, a novel drug delivery system using acidic oligopeptides to target the bone was
12 proposed. This unique approach is based on the physical properties of several non-collagenous
13 bone proteins that have repetitive sequences of acidic amino acids (L-Asp or L-Glu) and bind to
14 hydroxyapatite (15-17). Osteopontin and bone sialoprotein, two major non-collagenous proteins
15 in bone, have L-Asp and L-Glu repetitive sequences, respectively, and rapidly bind to
16 hydroxyapatite after secretion in osteoblastic cell culture (18-20). To determine the binding
17 affinity of acidic oligopeptides to hydroxyapatite, homopeptides consisting of two to ten residues
18 of acidic amino acids were conjugated with 9-fluorenylmethylchloroformate and the binding
19 affinities were investigated *in vitro*. The results indicated that the dissociation constants of the
20 acidic oligopeptides decreased with increasing numbers of acidic amino acid residues, and the
21 maximal binding rates reached a plateau at six residues, which were independent of acidic amino
22 acid specie (Asp or Glu) and optical isomeric form (L or D) (21). *In vivo*, fluorescein-labeled
23 L-Asp hexapeptide accumulated specifically in bone at 24 h after systemic administration in
24 mice and was not detected in other tissues. Surprisingly, fluorescein-labeled L-Asp hexapeptide
25 was detectable in bone 14 days after administration (22).
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Quinolones such as levofloxacin (LVFX) and norfloxacin (NFLX) have a broad spectrum
41 of activity *in vitro*, including activity against the Gram negative organisms, *S. aureus* and *S.*
42 *epidermidis*; therefore, increasing the quinolone concentration in bone should increase
43 therapeutic effectiveness in patients with osteomyelitis (23-25). In the present study, we
44 conjugated L-Asp hexapeptides to LVFX and NFLX, and evaluated their bone-targeting
45 properties and therapeutic effectiveness in a mouse model of osteomyelitis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Materials and Methods

Synthesis of L-Asp hexapeptide-conjugated levofloxacin

LVFX was esterified with glycolic acid before conjugation to L-Asp hexapeptide. Oxalyl chloride (2.76 mmol) was added to a cooled solution of LVFX (1.38 mmol) in dichloromethane (15 ml) including dimethylformamide (DMF; 0.1 ml), and the reaction mixture was stirred for 2 h at room temperature. Dichloromethane and unreacted oxalyl chloride were evaporated, and the samples were left until completely dry. The residue was dissolved in dichloromethane (10 ml), then dimethylaminopyridine (4.15 mmol) and benzyl glycolate (1.66 mmol) were added, and the solution was stirred overnight at 4°C. The resulting benzyl glycolyl ester of LVFX was purified by reverse-phase high performance liquid chromatography (RP-HPLC) with a YMC D-ODS-5 120A column (20 × 250 mm, YMC Co. Ltd., Kyoto, Japan) in 0.1% trifluoroacetic acid (TFA)-acetonitrile solvent at a flow rate of 8 ml/min and with monitoring at 210 nm. For the removal of benzyl by catalytic reduction, the benzyl glycolyl ester of LVFX was dissolved in methanol (10 ml) containing 0.5 ml of 50% acetic acid, and then a palladium suspension was added. The reaction mixture was stirred in a stream of hydrogen for 5 h at room temperature, followed by purification with RP-HPLC as described above. The resulting glycolyl ester of LVFX (LVFX-ga) was used in the conjugation reaction with L-Asp hexapeptide.

Starting with hydroxymethylphenoxymethyl resin (HMP resin or Wang resin) anchored with N^α -(9-fluorenylmethyloxycarbonyl)-L-aspartic acid β -tert-butyl ester [Fmoc-L-Asp(OBut)-OH], the Fmoc-[L-Asp(OBut)]₆-O-HMP-resin (0.30 mmol) was constructed using an Fmoc solid-phase method and a peptide synthesizer (ABI 433A; Applied Biosystems, CA, USA) and employing 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as a coupling reagent. The peptide resin was treated with 20% piperidine in *N*-methylpyrrolidone and was coupled with LVFX-ga (0.30 mmol) by *N,N'*-dicyclohexylcarbodiimide (DCC; 0.39 mmol) in a mixture of DMF (3 ml) and dichloromethane (15 ml) for 6 h. The resulting LVFX-ga-[Asp(OBut)]₆-O-HMP-resin was washed with DMF and dichloromethane-methanol (1:1) and was dried *in vacuo* prior to cleavage

1
2
3
4
5 and deprotection with 95% TFA (10 ml) at room temperature for 1.5 h. The resin was removed
6
7 by filtration, and the filtrate was evaporated and lyophilized. The crude product was purified by
8
9 RP-HPLC and lyophilized as described above. The synthesized LVFX-D₆ was subjected to fast
10
11 atom bombardment-mass spectroscopy (FAB-MS) analysis (JMS-DX300 mass spectrometer,
12
13 JEOL, Ltd., Tokyo, Japan).
14
15

16 17 **Synthesis of L-Asp hexapeptide-conjugated norfloxacin**

18
19 NFLX was amidated with glycolic acid, followed by esterification with succinic acid. To
20
21 a mixture of NFLX (1.57 mmol), glycolic acid (1.57 mmol), and N-methylmorpholine (3.13
22
23 mmol) in DMF (25 ml) was added *o*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium
24
25 hexafluorophosphate (1.57 mmol). The reaction mixture was stirred overnight at 4°C and then
26
27 evaporated until dry. The residue was washed with 50% methanol, 5% acetic acid, and dH₂O.
28
29 The resulting glycolyl-NFLX (NFLX-ga) was dried *in vacuo*. Succinic anhydride (3.18 mmol)
30
31 was added to the mixture of NFLX-ga (1.06 mmol) and dimethylaminopyridine (3.18 mmol) in
32
33 DMF (30 ml). The reaction mixture was stirred for 48 h at 4°C and then evaporated until dry.
34
35 The residue was washed with 3% acetic acid and then with dH₂O, followed by drying *in vacuo*.
36
37 The resulting NFLX-ga hemisuccinate (NFLX-ga-suc) was used for further conjugation with
38
39 L-Asp hexapeptide.

40
41 NFLX-ga-suc (0.30 mmol) and H-[Asp(OBut)]₆-O-HMP-resin (0.30 mmol) were reacted
42
43 in the presence of DCC (0.39 mmol) in the same manner as described above for the synthesis of
44
45 L-Asp hexapeptide-conjugated LVFX. The product was obtained by treating the resin with 95%
46
47 TFA, followed by purification with RP-HPLC and lyophilization. Synthesized NFLX-D₆ was
48
49 subjected to FAB-MS analysis.
50

51 52 **HPLC analysis**

53
54 The concentrations of LVFX, LVFX-D₆, NFLX, NFLX-ga, and NFLX-D₆ were
55
56 determined using an HPLC system (Shimadzu, Kyoto, Japan) equipped with a Shim-pack
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

CLC-ODS column (6 × 150 mm, Shimadzu). The mobile phase for LVFX, LVFX-D₆, NFLX, and NFLX-ga was 15% acetonitrile in 0.1% TFA, and that for NFLX-D₆ was 23% acetonitrile in 0.1% TFA. The flow rate was 1 ml/min. For fluorescence detection, the excitation and emission wavelengths were 296 nm and 500 nm, respectively, for LVFX and LVFX-D₆ and were 281 nm and 440 nm, respectively, for NFLX, NFLX-ga, and NFLX-D₆. The compounds were quantified by comparing the peak area ratio to standard curves generated from an internal standard (ciprofloxacin; CPMX).

Hydroxyapatite-binding assay

Hydroxyapatite beads (Bio-Rad Laboratories, CA, USA) were suspended in 50 mM Tris-HCl-buffered saline, pH 7.4, at a concentration of 100 µg/200 µl. LVFX, LVFX-D₆, NFLX, NFLX-ga, and NFLX-D₆ were respectively mixed with the hydroxyapatite suspension at final concentrations of 0.1, 0.3, 1.0, 3.0, 10.0, and 30 µM in a 400-µl final volume. The mixtures were agitated at 37°C for 1 h, followed by centrifugation at 12,000 × g for 5 min to capture the quinolone-bound hydroxyapatite beads. The supernatants were analyzed by HPLC to determine the amount of unbound quinolone. The amount of quinolone bound to the hydroxyapatite beads was calculated by subtracting the amount of unbound quinolone from the total amount of quinolone added to each tube.

Pharmacokinetic experiments and tissue distribution

All animal experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee of Kanazawa University. Experiments were performed using female ddY mice (8 to 10 weeks old). For the pharmacokinetic study, a dosage of 27.7 µmol/kg of LVFX or LVFX-D₆ (equivalent to 10 mg/kg LVFX), or a dosage of 31.3 µmol/kg of NFLX or NFLX-D₆ (equivalent to 10 mg/kg NFLX) was injected into the jugular vein of mice. Using heparinized capillary tubes, blood samples were collected from the intraorbital venous plexus of the mice under diethyl ether anesthesia at fixed time intervals. The plasma was separated by

1
2
3
4
5 centrifugation and stored at -80°C until assayed. Acetonitrile was added to each plasma sample,
6
7 and the samples were mixed by vortexing and then centrifuged at 12,000 × g for 10 min. Sample
8
9 supernatants were analyzed by HPLC. For determining tissue distribution, mice were sacrificed
10
11 by decapitation at 2 h after a single injection, and multiple tissues, including tibia, bone marrow,
12
13 brain, heart, lung, liver, spleen, intestine, kidney, and muscle, were dissected. The tibiae were
14
15 demineralized by incubation in 200 µl of concentrated HCl at 60°C for 2 h; then 400 µl of 10 M
16
17 NaOH were added, and the samples were mixed at room temperature for 3 h. The solutions were
18
19 neutralized by adding 200 µl of concentrated HCl and 1 ml of 1 M phosphate buffer (pH 7.0).
20
21 The other tissues were homogenized in saline, and 200 µl of each homogenate were mixed with
22
23 200 µl of 5 M NaOH at room temperature for 3 h. The solutions were neutralized by adding
24
25 200 µl of 5 M HCl and 1 ml of 1 M phosphate buffer. This method resulted in the hydrolysis of
26
27 more than 95% of LVFX-D₆ and NFLX-D₆ to LVFX and NFLX, respectively. To determine the
28
29 extent of biological hydrolysis of LVFX-D₆ and NFLX-D₆ to LVFX and NFLX-ga, respectively,
30
31 in the tissues, 1 ml of 1 M phosphate buffer was added to each tissue homogenate without the
32
33 addition of NaOH and HCl. The digested tissues were extracted twice with chloroform to recover
34
35 LVFX, NFLX, and NFLX-ga, and the combined chloroform extracts were evaporated. The
36
37 residues were reconstituted with a HPLC mobile phase; each sample was filtered through a
38
39 Millex-HV 0.45-µm filter (Millipore, MA, USA), and the flow-through was analyzed by HPLC.
40
41

42 **Antibiotic effectiveness in a mouse model of osteomyelitis**

43
44 Female ddY mice (8 to 10 weeks old) were inoculated with *S. aureus* (JCM 2413, RIKEN,
45
46 Saitama, Japan) to create experimental osteomyelitis. Briefly, the right tibia was exposed under
47
48 diethyl ether anesthesia, and a small hole was drilled in the proximal third portion of the tibia
49
50 with a 26-gauge needle. One microliter of an *S. aureus* suspension containing 10⁵
51
52 colony-forming units (cfu) was injected into the cavity, and the hole and skin were sealed with
53
54 medical tissue glue (Aron Alpha A, Sankyo Inc., Tokyo, Japan). On the following day,
55
56 110.7 µmol/kg of LVFX or LVFX-D₆ (equivalent to 40 mg/kg LVFX), or 125.3 µmol/kg of
57
58

1
2
3
4
5 NFLX or NFLX-D₆ (equivalent to 40 mg/kg NFLX) were injected via jugular vein. The mice
6
7 were sacrificed by decapitation at fixed time intervals, and the infected right tibiae were
8
9 dissected. Soft tissues were removed from the tibiae, and the tibiae were pulverized in 1 ml of
10
11 saline. The suspensions were serially diluted in saline, and 0.025-ml aliquots of each dilution
12
13 were plated onto Heart Infusion agar plates (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan). The
14
15 plates were incubated overnight at 37°C, and the colonies were counted.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results

Synthesis and antibiotic activity of L-Asp hexapeptide-conjugated quinolones

LVFX was conjugated with L-Asp hexapeptide via a glycolyl ester, and NFLX was conjugated via a glycolyl amide and subsequent succinate ester (Fig. 1). The synthetic yields of LVFX-D₆ and NFLX-D₆ from starting materials were 18.3 and 10.3%, respectively. The content of impurities such as LVFX in LVFX-D₆ and NFLX or NFLX-ga in NFLX-D₆ was approximately 0.5% for each preparation, as determined by HPLC analysis. The minimum inhibitory concentrations (MICs) of LVFX, LVFX-D₆, NFLX, NFLX-ga, and NFLX-D₆ with respect to *S. aureus* were determined by the serial dilution method (Table I). The conjugation of L-Asp hexapeptide significantly decreased the antibiotic activity of LVFX and NFLX; the activities of the non-conjugated forms were approximately 100-fold those of the conjugated forms. The MIC of NFLX-ga, which was expected to be generated through the biological hydrolysis of NFLX-D₆, was 50% of the MIC of NFLX.

Binding affinity of L-Asp hexapeptide-conjugated quinolones to hydroxyapatite

At concentrations of 10 nmol/ml and lower, the amounts of LVFX-D₆ and NFLX-D₆ that bound to hydroxyapatite were 10-fold the amounts of bound LVFX and NFLX, respectively (Fig. 2). However, the difference between the amounts of hydroxyapatite-bound LVFX and LVFX-D₆ was less at 30 nmol/ml (2.0 nmol of LVFX versus 3.4 nmol of LVFX-D₆ per 100 µg of hydroxyapatite). Appreciable quantities of NFLX and NFLX-ga did not bind to hydroxyapatite until their concentrations reached 30 µM.

Pharmacokinetics and tissue distribution of L-Asp hexapeptide-conjugated quinolones

After a single intravenous injection of LVFX, LVFX-D₆, NFLX, or NFLX-D₆, the concentrations of the compounds in bone and bone marrow were determined (Fig. 3). The amount of LVFX-D₆ in bone was approximately 100-fold that of LVFX at 2 h after injection, and LVFX-D₆ was retained in bone at a concentration 100-fold that of LVFX after 7 days.

1
2
3
4
5 Furthermore, the hydrolysis of LVFX-D₆ maintained LVFX in the bone marrow for at least 7
6 days, whereas in the group receiving LVFX, LVFX could not be detected in the bone marrow
7 after 1 day. Similarly, the level of NFLX-D₆ in bone was approximately 100-fold that of NFLX
8 at 3 days after injection, and substantial amounts of NFLX-D₆ were retained in bone for at least 7
9 days. NFLX was undetectable by day 7. Neither NFLX nor NFLX-ga was detectable in bone
10 marrow after an injection of NFLX or NFLX-D₆, respectively.
11
12

13
14
15 The plasma-concentration time courses of LVFX, LVFX-D₆, NFLX, and NFLX-D₆ after
16 a single intravenous injection revealed biphasic behavior of these compounds (Fig. 4). The
17 plasma concentrations of the conjugated quinolones were 2- to 3-fold those of the
18 non-conjugated quinolones initially after injection, whereas the half-life in the plasma was
19 similar between the conjugated and non-conjugated quinolones during the elimination phase. The
20 plasma concentrations of LVFX-D₆ and NFLX-D₆ were higher than those of LVFX and NFLX,
21 respectively, immediately after injection, but they rapidly decreased, falling to levels similar to
22 those of LVFX and NFLX by 30 min. After an injection of LVFX-D₆, LVFX, which might have
23 been generated from LVFX-D₆, appeared in the plasma; its concentration slowly decreased, and
24 LVFX was not detectable after 90 min. In contrast, NFLX and NFLX-ga were not detected in the
25 plasma until 6 h after an injection of NFLX-D₆.
26
27

28
29 At 2 h after a single intravenous injection, the apparent plasma-to-tissue concentration
30 ratios ($K_{p,app}$) of LVFX, LVFX-D₆, NFLX, and NFLX-D₆ were determined (Fig. 5). In most of
31 the soft tissues examined, except lung and kidney tissues, LVFX-D₆ exhibited a restricted tissue
32 distribution relative to LVFX after the injection of each, and LVFX was not detected in any of
33 the soft tissues after an LVFX-D₆ injection. NFLX-D₆ also exhibited more limited tissue
34 distribution, except in kidney tissue, than NFLX after their respective injections, and neither
35 NFLX nor NFLX-ga was detected in the soft tissues after NFLX-D₆ injection.
36
37

38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 **Antibiotic effectiveness of L-Asp hexapeptide-conjugated quinolones in a mouse model of** 55 **osteomyelitis** 56

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The antibiotic effectiveness of LVFX, LVFX-D₆, NFLX, and NFLX-D₆ was evaluated by counting the *S. aureus* colonies remaining in inoculated tibiae after a single intravenous injection of each compound (Fig. 6). In untreated control mice, the cfu of *S. aureus* reached a plateau at 2 days after inoculation. With the injection of either LVFX or LVFX-D₆ on the day following *S. aureus* inoculation, a slight reduction in cfu was observed. However, the antibiotic effectiveness of LVFX was temporary; after 6 days, the cfu recovered to levels similar to those in untreated control mice. A prolonged antibiotic effect was observed in mice treated with LVFX-D₆, which suppressed the growth of *S. aureus* for at least 6 days. Conversely, neither NFLX nor NFLX-D₆ displayed any antibiotic efficacy in the osteomyelitis mouse model (data not shown).

1
2
3
4
5
6 **Discussion**

7 In this study we examined the pharmacokinetics and pharmacodynamics of quinolones
8 conjugated with L-Asp hexapeptide as a bone-targeting carrier. We demonstrated that the
9 conjugated quinolones localize to bone, where they were retained for longer times compared
10 with the non-conjugated quinolones and exhibit prolonged antibiotic effects in mice with
11 osteomyelitis.
12
13
14
15
16

17 Quinolones act by inhibiting bacterial topoisomerase II, which is responsible for the
18 replication of double-stranded DNA, and they therefore must cross the bacterial membrane to be
19 effective (26, 27). Specifically, the 3-carboxylate group, a basic structure of quinolones, mediates
20 binding to topoisomerase II (28). As this structure would be obstructed by the direct conjugation
21 of LVFX to the L-Asp hexapeptide moiety, we created a glycolyl ester of LVFX in order to
22 introduce a biologically hydrolysable spacer between LVFX and the L-Asp hexapeptide. To
23 avoid modification of the 3-carboxylate moiety of NFLX, we conjugated L-Asp hexapeptide to
24 the secondary amine of the piperazine ring. However, NFLX-D₆ had substantially reduced
25 antibiotic activity compared with NFLX and NFLX-ga. It is well known that the accumulation of
26 quinolones in Gram-positive bacteria correlates with the hydrophobicity of the molecule, which
27 implies that quinolones cross bacterial membranes by simple diffusion (29-31). The partition
28 coefficients of the conjugated quinolones in n-octanol/aqueous buffer and chloroform/aqueous
29 buffer were approximately 100-fold less than those of the non-conjugated quinolones (data not
30 shown). Thus, the conjugation of hydrophilic amino acids, specifically L-Asp hexapeptide,
31 reduced the hydrophobicity of the quinolones, and the conjugated quinolones could not cross the
32 bacterial membrane until the L-Asp hexapeptide was removed by ester hydrolysis.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Compared with the non-conjugated quinolones, the conjugated quinolones exhibited
49 increased binding affinity to hydroxyapatite *in vitro* and consistently higher bone concentrations
50 *in vivo*. Furthermore, the hydrolyzed product of LVFX-D₆, LVFX, was detected in the plasma
51 and bone marrow after the injection of LVFX-D₆. These findings strongly support using
52 LVFX-D₆ as an osteomyelitis treatment. Indeed, LVFX-D₆ suppressed the growth of *S. aureus*
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 for at least 6 days in a mouse model of osteomyelitis, thus exhibiting prolonged antibiotic
6 activity. However, the antibiotic effect of LVFX-D₆ was not entirely bactericidal, presumably
7 because the concentration of LVFX generated from hydrolyzed LVFX-D₆ was insufficient to kill
8 *S. aureus* in bone. NFLX-D₆ showed no efficacy in this model of osteomyelitis, nevertheless
9 NFLX-D₆ was highly accumulated in bone at approximately 5-fold the concentration of
10 LVFX-D₆. The 3-carboxylate and 4-carbonyl groups in quinolone are known to be responsible
11 for potential chelating property with divalent metals such as calcium existing in bone, and these
12 groups remain intact in NFLX-D₆, but not in LVFX-D₆ (32). It is also known that the extension
13 of the number of acidic amino acid increases the bone accumulating property of acidic
14 oligopeptide *in vivo* (21). Thus, it was hypothesized that the intact 3-carboxylate and 4-carbonyl
15 groups in NFLX-D₆ further augmented the affinity of L-Asp hexapeptide to bone. Although the
16 hydrolyzed product of NFLX-D₆, NFLX-ga, was not detected in bone marrow after an injection
17 of NFLX-D₆, this might be attributable to a lower detection limit of NFLX-ga compared with
18 LVFX. Given the similar decline in the bone concentrations of NFLX-D₆ and LVFX-D₆,
19 NFLX-ga might be continuously released. Taken together, we expect that the limited
20 effectiveness of NFLX-D₆ in this model of osteomyelitis may be due to both NFLX and
21 NFLX-ga have lower antibiotic activity toward *S. aureus* compared with LVFX. The bactericidal
22 effect of quinolones is concentration dependent, with a higher concentration of quinolone
23 producing a more complete killing effect (33, 34). Thus, a high hydrolytic rate of the conjugated
24 quinolones appears to be important for maximal antibiotic effect.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Quinolones extensively penetrate tissues and consequently may cause adverse effects in the cardiovascular system, central nervous system, skin, liver, musculoskeletal system, and kidneys (35-37). The conjugated quinolones showed reduced tissue distribution, probably owing to their increased hydrophilicity. Both LVFX-D₆ and NFLX-D₆ were distributed to the kidneys at concentrations 2- to 3-fold those of LVFX and NFLX, respectively, at 2 h after injection. However, the levels of the conjugated quinolones returned to those of the non-conjugated quinolones by 4 h (Fig 7). Quinolones are excreted entirely via the kidneys, and the increased

1
2
3
4
5 hydrophilicity of the conjugated quinolones may facilitate their accumulation in the kidneys (38,
6 39). This renal accumulation may also be partly due to the higher plasma concentration, which is
7 a result of the lower tissue distribution, at an early time after injection. In addition, the acidic
8 oligopeptide was eliminated by renal excretion, and the plasma half-life decreased with
9 increasing number of acidic amino acid residues (21). Thus, the L-Asp hexapeptide altered the
10 renal distribution of quinolones, although the influence of L-Asp hexapeptide on the renal
11 pharmacokinetics, including glomerular filtration, tubular secretion, and tubular re-absorption,
12 remains to be solved. The accumulation of conjugated quinolones could increase the risk of
13 adverse events such as azotemia, nephropathy, and interstitial nephritis; meanwhile, the risk of
14 adverse events involving other tissues may be decreased.
15
16
17
18
19
20
21
22
23
24

25 When conjugated to an acidic oligopeptide, the common quinolones LVFX and NFLX
26 are model drugs that highlight the clinical feasibility of using a bone-targeting strategy in the
27 treatment of osteomyelitis. To increase the therapeutic effectiveness of this treatment strategy,
28 other compounds with greater initial antibiotic activity could be used, as peptide conjugation is
29 applicable to molecules of all sizes, including enzymes (22, 40-42). Further modifications should
30 also be considered to ensure biological hydrolysis of acidic oligopeptide-conjugated compounds,
31 although the mechanism of hydrolysis remains to be resolved.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 **References**

- 7 1. W.G. Cole, R.E. Dalziel, and S. Leidl. Treatment of acute osteomyelitis in childhood. *J Bone*
8 *Joint Surg Br.* 64: 218-223 (1982).
9
10 2. E.P. Armstrong and D.R. Rush. Treatment of osteomyelitis. *Clin Pharm.* 2: 213-224 (1983).
11
12 3. D.R. Dirschl and L.C. Almekinders. Osteomyelitis. Common causes and treatment
13 recommendations. *Drugs.* 45: 29-43 (1993).
14
15 4. D.P. Lew and F.A. Waldvogel. Osteomyelitis. *N Engl J Med.* 336: 999-1007 (1997).
16
17 5. P.J. Carek, L.M. Dickerson, and J.L. Sack. Diagnosis and management of osteomyelitis. *Am*
18 *Fam Physician.* 63: 2413-2420 (2001).
19
20 6. J.T. Mader, M. Ortiz, and J.H. Calhoun. Update on the diagnosis and management of
21 osteomyelitis. *Clin Podiatr Med Surg.* 13: 701-724 (1996).
22
23 7. J.T. Mader, D. Mohan, and J. Calhoun. A practical guide to the diagnosis and management of
24 bone and joint infections. *Drugs.* 54: 253-264 (1997).
25
26 8. M.P. Weinstein, C.W. Stratton, H.B. Hawley, A. Ackley, and L.B. Reller. Multicenter
27 collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic
28 efficacy in acute and chronic osteomyelitis. *Am J Med.* 83: 218-222 (1987).
29
30 9. K.W. Klemm. Antibiotic bead chains. *Clin Orthop Relat Res.* 295: 63-76 (1993).
31
32 10. D.A. Winingar and R.J. Fass. Antibiotic-impregnated cement and beads for orthopedic
33 infections. *Antimicrob Agents Chemother.* 40: 2675-2679 (1996).
34
35 11. C.G. Ambrose, G.R. Gogola, T.A. Clyburn, A.K. Raymond, A.S. Peng, and A.G. Mikos.
36 Antibiotic microspheres: preliminary testing for potential treatment of osteomyelitis. *Clin Orthop*
37 *Relat Res.* 415: 279-285 (2003).
38
39 12. C.G. Ambrose, T.A. Clyburn, K. Loudon, J. Joseph, J. Wright, P. Gulati, G.R. Gogola, and
40 A.G. Mikos. Effective treatment of osteomyelitis with biodegradable microspheres in a rabbit
41 model. *Clin Orthop Relat Res.* 421: 293-299 (2004).
42
43 13. B. Buranapanitkit, V. Srinilta, N. Ingvinga, K. Oungbho, A. Geater, and C. Ovatlarnporn. The
44 efficacy of a hydroxyapatite composite as a biodegradable antibiotic delivery system. *Clin*
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 Orthop Relat Res. 424: 244-252 (2004).
6

7 14. U. Joosten, A. Joist, G. Gosheger, U. Liljenqvist, B. Brandt, and C. von Eiff. Effectiveness of
8 hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced
9 chronic osteomyelitis. *Biomaterials*. 26: 5251-5258 (2005).
10

11 15. A. Oldberg, A. Franzén, and D. Heinegård. Cloning and sequence analysis of rat bone
12 sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. *Proc Natl Acad*
13 *Sci U S A*. 83: 8819-8823 (1986).
14

15 16. A. Oldberg, A. Franzén, and D. Heinegård. The primary structure of a cell-binding bone
16 sialoprotein. *J Biol Chem*. 263: 19430-19432 (1988).
17

18 17. W.T. Butler. The nature and significance of osteopontin. *Connect Tissue Res*. 23: 123-136
19 (1989).
20

21 18. T. Nagata, C.G. Bellows, S. Kasugai, W.T. Butler, and J. Sodek. Biosynthesis of bone
22 proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC
23 (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in
24 culture. *Biochem J*. 274: 513-520 (1991).
25

26 19. S. Kasugai, R. Todescan Jr., T. Nagata, K.L. Yao, W.T. Butler, and J. Sodek. Expression of
27 bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells
28 in vitro: inductive effects of dexamethasone on the osteoblastic phenotype. *J Cell Physiol*. 147:
29 111-120 (1991).
30

31 20. S. Kasugai, T. Nagata, and J. Sodek. Temporal studies on the tissue compartmentalization of
32 bone sialoprotein (BSP), osteopontin (OPN), and SPARC protein during bone formation in vitro.
33 *J Cell Physiol*. 152: 467-477 (1992).
34

35 21. T. Sekido, N. Sakura, Y. Higashi, K. Miya, Y. Nitta, M. Nomura, H. Sawanishi, K. Morito, Y.
36 Masamune, S. Kasugai, K. Yokogawa, and K. Miyamoto. Novel drug delivery system to bone
37 using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. *J Drug*
38 *Target*. 9: 111-121 (2001).
39

40 22. S. Kasugai, R. Fujisawa, Y. Waki, K. Miyamoto, and K Ohya. Selective drug delivery system
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 to bone: small peptide (Asp)₆ conjugation. *J Bone Miner Res.* 15: 936-943 (2000).

6
7 23. I. Phillips, A. King, and K. Shannon. In vitro properties of the quinolones. In V.T. Andriole
8 (ed.), *The quinolones*, Academic Press, New York, 1988, pp. 83-117.

9
10 24. J.T. Mader. Fluoroquinolones in bone and joint infections. In W.E. Sanders Jr. and C.C.
11 Sanders (eds.), *Fluoroquinolones in the treatment of infectious diseases*, Physicians & Scientists,
12 Illinois, 1990, pp. 71-86.

13
14 25. J.T. Mader, J.S. Cantrell, and J. Calhoun. Oral ciprofloxacin compared with standard
15 parenteral antibiotic therapy for chronic osteomyelitis in adults. *J Bone Joint Surg Am.* 72:
16 104-110 (1990).

17
18 26. R.J. Lewis, F.T. Tsai, and D.B. Wigley. Molecular mechanisms of drug inhibition of DNA
19 gyrase. *Bioessays.* 18: 661-671 (1996).

20
21 27. L.L. Shen and D.T.W. Chu. Type II DNA topoisomerases as antibacterial targets. *Curr Pharm*
22 *Des.* 2: 195-208 (1996).

23
24 28. T.D. Gootz and K.E. Brighty. Fluoroquinolone antibacterials: SAR mechanism of action,
25 resistance, and clinical aspects. *Med Res Rev.* 16: 433-486 (1996).

26
27 29. Y. Hidakata, M. Kaku, R. Mizukane, K. Ishida, N. Furuya, T. Matsumoto, K. Tateda, and K.
28 Yamaguchi. Potential effects of erythromycin on host defense systems and virulence of
29 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 36: 1922-1927 (1992).

30
31 30. S. Bazile, N. Moreau, D. Bouzard, and M. Essiz. Relationships among antibacterial activity,
32 inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. *Antimicrob*
33 *Agents Chemother.* 36: 2622-2627 (1992).

34
35 31. L.J. Piddock, Y.F. Jin, and D.J. Griggs. Effect of hydrophobicity and molecular mass on the
36 accumulation of fluoroquinolones by *Staphylococcus aureus*. *J Antimicrob Chemother.* 47:
37 261-270 (2001).

38
39 32. J.M. Domagala. Structure-activity and structure-side-effect relationships for the quinolone
40 antibacterials. *J Antimicrob Chemother.* 33: 685-706 (1994).

41
42 33. J. Blaser, B.B. Stone, M.C. Groner, and S.H. Zinner. Comparative study with enoxacin and
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6 netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak
7 concentration to MIC for bactericidal activity and emergence of resistance. *Antimicrob Agents*
8 *Chemother.* 31: 1054-1060 (1987).
9
10
11 34. S.L. Preston, G.L. Drusano, A.L. Berman, C.L. Fowler, A.T. Chow, B. Dornseif, V. Reichl, J.
12 Natarajan, and M. Corrado. Pharmacodynamics of levofloxacin: a new paradigm for early
13 clinical trials. *JAMA.* 279: 125-129 (1998).
14
15
16 35. J.M. Blondeau. Expanded activity and utility of the new fluoroquinolones: a review. *Clin*
17 *Ther.* 21: 3-40 (1999).
18
19
20 36. J.J. Schentag and B.E. Scully. Antibacterial agents-quinolones. In V.L. Yu and T.C. Merigan
21 Jr. (eds.), *Antimicrobial therapy and vaccines*, Williams & Wilkins, Baltimore, 1999, pp.
22 875-901.
23
24
25 37. J.A. O'Donnell and S.P. Gelone. Fluoroquinolones. *Infect Dis Clin North Am.* 14: 489-513
26 (2000).
27
28
29 38. R. Davis and H.M. Bryson. Levofloxacin. A review of its antibacterial activity,
30 pharmacokinetics and therapeutic efficacy. *Drugs.* 47: 677-700 (1994).
31
32
33 39. P. Ball. The quinolones, history and overview. In V.T. Andriole (ed.), *The quinolones*,
34 Academic Press, New York, 1998, pp. 1-28.
35
36
37 40. K. Yokogawa, K. Miya, T. Sekido, Y. Higashi, M. Nomura, R. Fujisawa, K. Morito, Y.
38 Masamune, Y. Waki, S. Kasugai, and K Miyamoto. Selective delivery of estradiol to bone by
39 aspartic acid oligopeptide and its effects on ovariectomized mice. *Endocrinology.* 142:
40 1228-1233 (2001).
41
42
43 41. T. Nishioka, S. Tomatsu, M.A. Gutierrez, K. Miyamoto, G.G. Trandafirescu, P.L. Lopez, J.H.
44 Grubb, R. Kanai, H. Kobayashi, S. Yamaguchi, G.S. Gottesman, R. Cahill, A. Noguchi, and W.S.
45 Sly. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific
46 alkaline phosphatase tagged with an acidic oligopeptide. *Mol Genet Metab.* 88: 244-255 (2006).
47
48
49 42. J.L. Millán, S. Narisawa, I. Lemire, T.P. Loisel, G. Boileau, P. Leonard, S. Gramatikova, R.
50 Terkeltaub, N. Pleshko Camacho, M.D. McKee, P. Crine, and M.P. Whyte. Enzyme replacement
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

therapy for murine hypophosphatasia. J Bone Miner Res. in press (2007).

1
2
3
4
5
6 **Figure legends**

7 **Fig. 1.** Molecular structures of LVFX, glycolyl ester of LVFX (LVFX-ga), LVFX-D₆, NFLX,
8 glycolyl-NFLX (NFLX-ga), glycolyl-NFLX hemisuccinate (NFLX-ga-suc), and NFLX-D₆.
9

10
11
12
13 **Fig. 2.** Concentration-dependent binding curves of L-Asp hexapeptide-conjugated and
14 non-conjugated quinolones to hydroxyapatite. Final concentrations of 0.1 to 30 μ M of each
15 compound, A) LVFX (\circ) and LVFX-D₆ (\bullet), and B) NFLX (\circ), NFLX-ga (\triangle), and NFLX-D₆
16 (\bullet), were incubated with 100 μ g of hydroxyapatite at 37°C for 1 h. The unbound quinolone was
17 separated from the bound quinolone by centrifugation and the concentration of unbound
18 quinolone in the supernatant was measured. The amount of bound quinolone was calculated by
19 subtracting the unbound from the total. L-Asp hexapeptide conjugation significantly increased
20 the binding affinity of quinolones to hydroxyapatite. Each point with a bar represents the mean \pm
21 SE of 3-6 experiments.
22
23
24
25
26
27
28
29
30

31
32
33 **Fig. 3.** Time course of bone and bone marrow concentrations of L-Asp hexapeptide-conjugated
34 and non-conjugated quinolones. A dosage of A) 27.7 μ mol/kg of LVFX (\circ) or LVFX-D₆ (\bullet), or
35 B) 31.3 μ mol/kg of NFLX (\circ) or NFLX-D₆ (\bullet) was intravenously injected into mice, and the
36 concentrations in the tibia were determined at the indicated time points. The L-Asp
37 hexapeptide-conjugated quinolones were concentrated and retained in bone at approximately
38 100-fold the concentrations of non-conjugated quinolones for at least 7 days after injection. C) In
39 bone marrow, LVFX was detected at 2 h after an injection of LVFX (\circ) or LVFX-D₆ (\bullet). The
40 LVFX concentration declined to an undetectable level within 1 day after LVFX injection,
41 whereas LVFX continued to be generated for at least 7 days after LVFX-D₆ injection. Neither
42 NFLX nor NFLX-ga was detected in bone marrow after injection of either NFLX or NFLX-D₆,
43 respectively. Each point with a bar represents the mean \pm SE of four mice.
44
45
46
47
48
49
50
51
52
53
54

55
56 **Fig. 4.** Time course of plasma concentrations of L-Asp hexapeptide-conjugated and
57
58
59
60
61
62
63
64
65

1
2
3
4
5 non-conjugated quinolones. A dosage of A) 27.7 $\mu\text{mol/kg}$ of LVFX (\circ) or LVFX-D₆ (\bullet), or B)
6 31.3 $\mu\text{mol/kg}$ of NFLX (\circ) or NFLX-D₆ (\bullet) was intravenously injected into mice, and the
7 concentrations in plasma were determined at the indicated time points. All the compounds were
8 eliminated from the plasma in a biphasic manner. The plasma concentrations of the conjugated
9 quinolones were 2- to 3-fold those of the non-conjugated quinolones initially after injection.
10 However, the half-life was similar between the conjugated and non-conjugated quinolones during
11 the elimination phase. The hydrolyzed product LVFX (\blacksquare), which was shown in A), was detected
12 in the plasma after LVFX-D₆ injection, and LVFX was eliminated slowly from the plasma. The
13 predicted hydrolyzed products of NFLX-D₆ (NFLX and NFLX-ga) were not detected in the
14 plasma after NFLX-D₆ injection. Each point with a bar represents the mean \pm SE of four mice.
15
16
17
18
19
20
21
22
23
24
25
26

27 **Fig. 5.** Tissue distribution of L-Asp hexapeptide-conjugated and non-conjugated quinolones. A
28 dosage of A) 27.7 $\mu\text{mol/kg}$ of LVFX (\square) or LVFX-D₆ (\blacksquare), or B) 31.3 $\mu\text{mol/kg}$ of NFLX (\square) or
29 NFLX-D₆ (\blacksquare) was intravenously injected into mice, and the concentration of each compound
30 was determined in the indicated tissues at 2 h after injection. The amounts of the L-Asp
31 hexapeptide-conjugated quinolones were less than the amounts of the non-conjugated quinolones
32 in most tissues, with the exception of lung and kidney tissues. The predicted products of
33 hydrolysis (LVFX, NFLX, and NFLX-ga) were not detected in any of the soft tissues examined.
34 Each column with a bar represents the mean \pm SE of four mice. $K_{p,app}$; apparent
35 plasma-to-tissue concentration ratios.
36
37
38
39
40
41
42
43
44
45

46 **Fig. 6.** Antibiotic effectiveness of LVFX and LVFX-D₆ in a mouse model of osteomyelitis. One
47 microliter containing 10^5 cfu of *S. aureus* was inoculated into the tibiae of mice. The following
48 day, LVFX (\circ) or LVFX-D₆ (\bullet) at 110.7 $\mu\text{mol/kg}$ was intravenously injected, and the quantity
49 of surviving *S. aureus* colonies was determined at the indicated time points. The cfu in untreated
50 control mice (\triangle) reached a plateau 2 days post-inoculation, whereas both LVFX and LVFX-D₆
51 significantly suppressed the growth of *S. aureus*. The antibiotic efficacy of LVFX-D₆ continued
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 for at least 6 days after injection, but the effectiveness of LVFX was temporary. Each point with
6 a bar represents the mean \pm SE of 8-12 mice. *, **; significantly different from untreated control
7 mice at $p < 0.05$ and $p < 0.01$, respectively. †; significantly different from LVFX-treated mice at
8 $p < 0.01$.
9
10
11
12
13
14

15 **Fig. 7.** Time course of kidney concentrations of L-Asp hexapeptide-conjugated and
16 non-conjugated quinolones. A dosage of A) 27.7 $\mu\text{mol/kg}$ of LVFX (\circ) or LVFX-D₆ (\bullet), or B)
17 31.3 $\mu\text{mol/kg}$ of NFLX (\circ) or NFLX-D₆ (\bullet) was intravenously injected into mice, and the
18 concentrations in kidney were determined at the indicated time points. The L-Asp
19 hexapeptide-conjugated quinolones were concentrated in kidney at approximately two-fold the
20 concentrations of non-conjugated quinolones at 2 h after injection. At 4 h, however, the kidney
21 concentrations of the L-Asp hexapeptide-conjugated quinolones fell in the similar level as
22 non-conjugated quinolones. Each point with a bar represents the mean \pm SE of four mice.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 **Table I.** *In vitro* antibiotic activities of L-Asp hexapeptide-conjugated and non-conjugated
6 quinolones against *Staphylococcus aureus*.
7
8


9

Compound	MIC ^a (nmol/ml)
LVFX	0.35
LVFX-D ₆	44.3
NFLX	3.13
NFLX-ga	6.26
NFLX-D ₆	200


10
11
12
13
14
15
16
17
18
19
20
21

22 ^aMIC, minimum inhibitory concentration; the lowest concentration of a compound that inhibited
23 visible growth of *S. aureus* after overnight incubation at 37°C in Mueller-Hinton broth.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


1
2
3
4
5 **Fig. 1**
6
7
8
9




1
2
3
4
5 **Fig. 2**
6
7





1
2
3
4
5 **Fig. 3**
6
7




1
2
3
4
5 **Fig. 4**
6
7




1
2
3
4
5 **Fig. 5**
6
7



1
2
3
4
5
6 **Fig. 6**



1
2
3
4
5 **Fig. 7**
6
7



Re: PharmRes3191, Bone-targeting of quinolones conjugated with an acidic oligopeptide

Dear Dr. Wang,

Thank you for your reviewing our manuscript. We revised our manuscript according to the reviewer comments. We hope that this revised version will be accepted for publication in a timely manner.

Sincerely,

Ken-ichi Miyamoto, Ph.D.

Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University

13-1 Takara-machi, Kanazawa 920-8641, Japan

Tel: +81-76-265-2045

FAX: +81-76-234-4280

E-mail: miyaken@kenroku.kanazawa-u.ac.jp

Reviewer #1: Miyamoto et al. synthesized levofloxacin and norfloxacin - (L-Asp)₆ conjugates and studied their bone-targeting capacity and therapeutic effectiveness in a mouse model of osteomyelitis. The manuscript is suitable for publication after the following points have been addressed:

1. Please, comment on the pros and cons of using (L-Asp)₆ vs. (D-Asp)₆ as targeting moieties.

Ans. The affinity of acidic oligopeptide for hydroxyapatite was not related to optical isomeric

form (L or D). For that reason, we chose the physiologically major form, L, and it was described in the 3rd paragraph of Introduction.

2. Explain why LVFX was modified as an ester, whereas NFLX as an amide.

Ans. The reason was explained in 2nd paragraph of Discussion. A 3-carboxylate group in LVFX is available for the conjugation with an L-Asp hexapeptide. Since the 3-carboxylate group is essential for bactericidal activity, the conjugated L-Asp hexapeptide must be removed. That was why we modified LVFX as an ester which is a well-known as biologically hydrolysable bond. We also tried to conjugate an L-Asp hexapeptide to another moiety of quinolone except active site. NFLX has a modifiable secondary amine of the piperazine ring, although it is impossible to create an ester directly. That was why we could only modified NFLX as an amide. We made, of course, an ester bond between the moieties of glycolyl-NFLX amide and L-Asp hexapeptide, so L-Asp hexapeptide could be removed in body.

3. The kidney accumulation of the conjugates is an important observation. Is the location of the conjugate known? Did it re-absorb in proximal tubuli?

Ans. We expect that the accumulation of the conjugated quinolones in kidney may be partly caused by the increased hydrophilicity and the subsequent higher plasma concentration, which is a result of the lower tissue distribution, at an early time after injection. Both LVFX and NFLX are exclusively eliminated by renal excretion and, in addition, the acidic oligopeptide is also eliminated by renal excretion with shorter plasma half-life as increasing number of acidic amino acid residues. Thus, the L-Asp hexapeptide altered the renal distribution of quinolones, although the influence of L-Asp hexapeptide on the renal pharmacokinetics, including glomerular filtration, tubular secretion, and tubular re-absorption, remains to be solved.

The above-mentioned hypothesis was described in the 4th paragraph of Discussion.

4. The kidney levels at 4 h are an important fact. At present the authors only stated that the

concentration of conjugates was similar to those of unconjugated quinolones and do not show data. It is important to present the experimental data for kidney at 4 h!

Ans. The figure of kidney concentration time-course was presented in new Figure 7.

5. The differences in bone marrow accumulation of the two conjugates (Fig. 3) should be discussed. Propose a hypothesis.

Ans. We expect that the hydrolyzed product of NFLX-D₆, NFLX-ga, might be continuously released in bone marrow, since NFLX-D₆ and LVFX-D₆ gave the similar decline in the bone concentrations. The reason of the observed differences in bone marrow accumulation was attributable for a lower detection limit of NFLX-ga than LVFX.

The differences in bone accumulation of LVFX-D₆ and NFLX-D₆ were also observed. NFLX-D₆ was accumulated in bone 5-fold higher than LVFX-D₆. The 3-carboxylate and 4-carbonyl groups in quinolone are known to be responsible for potential chelating property with divalent metals such as calcium existing in bone, and these groups remain intact in NFLX-D₆, but not in LVFX-D₆. It is also known that the extension of the number of acidic amino acid increases the bone accumulating property of acidic oligopeptide in vivo. Taken together, it was hypothesized that the intact 3-carboxylate and 4-carbonyl groups in NFLX-D₆ further augmented the affinity of L-Asp hexapeptide to bone.

The above-mentioned hypothesis was described in the 3rd paragraph of Discussion.

Reviewer #2: This is a well-written manuscript that provides some new insights into possible future treatments of osteomyelitis. The experiments are presented very well. While certainly not necessary, I wonder if the authors might speculate on what strategies might be used to improve the in vivo efficacy of the conjugated quinolones, or other antibiotics.

Ans. We speculate that a high hydrolytic rate of acidic oligopeptide-conjugated quinolones can

be more effective in vivo, although it is still unknown what factor determines the half-life of the conjugated quinolones in bone as described in the 3rd and last paragraphs of Discussion. We can propose a possible strategy to improve the efficacy, such as devising a linkage susceptible to osteoclast-derived acid, or peptidase, or nonspecific esterase.

Minor comments

1. Line 23 in last paragraph of the Methods. It might be helpful if the route of the iv injection was indicated, for example, tail vein.

Ans. We indicated the route of iv injection, which was via jugular vein, in last paragraph of the Methods.

2. First paragraph of the Discussion. I suggest that in line 13 the "are" be replaced with "were", since you are discussing a prior result (past tense).

Ans. We replaced "are" with "were".

3. The legends to Figures 3 and 4 are a bit confusing. It is not indicated in which figure the square black box is in. While it is apparent that it is in the A figure, it should be indicated as such in the legend. This is particularly confusing since bone and bone marrow are in the same figure.

Ans. In Figure 3, we separated the figure of bone marrow concentration and it was shown as Figure 3C. In Figure 4, we described that the square black box was shown A figure in the legend.

4. Figure 5. For the general reader, it might be a good idea to include in the figure legend that the $K_{p,app}$ is the "plasma-to-tissue concentration ratios".

Ans. We described that the $K_{p,app}$ is the "plasma-to-tissue concentration ratios" in the legend.